<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lobb TA</submitter><funding>NIDA NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>ORFDO NIH HHS</funding><pagination>41</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12873219</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>Type I interferons (IFN) are key mediators of innate immune activation, promoting upregulation of costimulatory molecules and Major Histocompatibility Complex (MHC) I/II on antigen-presenting cells (APCs). However, IFN also suppress endogenous translation to restrict viral replication. Critically, IFN-stimulated APCs lose the capacity to acquire new antigens, making the timing of IFN signaling a crucial determinant of vaccine efficacy. Here, we show that both DC-specific loss of IFNα/β receptor (IFNαR) and transient blockade of IFNαR before vaccination enhances vaccine uptake and expression within DCs, improves CD8⁺ T cell priming, and leads to superior tumor control. We also demonstrate that IFN signaling before vaccination, triggered by prior infection or administration of a different va</pubmed_abstract><journal>NPJ vaccines</journal><pubmed_title>Type I interferon restricts mRNA vaccine efficacy through suppression of antigen uptake in cDCs.</pubmed_title><pmcid>PMC12873219</pmcid><funding_grant_id>75N99020D00005</funding_grant_id><funding_grant_id>75N95020D00005</funding_grant_id><funding_grant_id>75N93022D00005</funding_grant_id><funding_grant_id>75N92020D00005</funding_grant_id><funding_grant_id>75N93023D00005</funding_grant_id><pubmed_authors>DiPaolo RJ</pubmed_authors><pubmed_authors>Ferris ST</pubmed_authors><pubmed_authors>Dickson A</pubmed_authors><pubmed_authors>Carrero JA</pubmed_authors><pubmed_authors>Guo W</pubmed_authors><pubmed_authors>Dalben Y</pubmed_authors><pubmed_authors>Alspach E</pubmed_authors><pubmed_authors>Tse LV</pubmed_authors><pubmed_authors>Lobb TA</pubmed_authors><pubmed_authors>Beeram S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Type I interferon restricts mRNA vaccine efficacy through suppression of antigen uptake in cDCs.</name><description>Type I interferons (IFN) are key mediators of innate immune activation, promoting upregulation of costimulatory molecules and Major Histocompatibility Complex (MHC) I/II on antigen-presenting cells (APCs). However, IFN also suppress endogenous translation to restrict viral replication. Critically, IFN-stimulated APCs lose the capacity to acquire new antigens, making the timing of IFN signaling a crucial determinant of vaccine efficacy. Here, we show that both DC-specific loss of IFNα/β receptor (IFNαR) and transient blockade of IFNαR before vaccination enhances vaccine uptake and expression within DCs, improves CD8⁺ T cell priming, and leads to superior tumor control. We also demonstrate that IFN signaling before vaccination, triggered by prior infection or administration of a different va</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-15T13:33:27.77Z</modification><creation>2026-07-05T03:08:22.022Z</creation></dates><accession>S-EPMC12873219</accession><cross_references><pubmed>41486285</pubmed><doi>10.1038/s41541-025-01362-z</doi></cross_references></HashMap>